ArticleCureus2025
Efficacy of Tranexamic Acid in Reducing Blood Loss During Percutaneous Nephrolithotomy: An Interventional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Tranexamic acid for prevention of bleeding complications-a rational approach? : Results of a systematic literature review and evidence synthesis].Urologie (Heidelberg, Germany) · 2026Pooled it
- Effect of tranexamic acid irrigation on perioperative blood loss during mini-percutaneous nephrolithotomy: A pilot double-blind randomised controlled trial.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn interventional study was conducted in the Department of Urology at a tertiary care center in Dehradun, India, to assess the efficacy of tranexamic acid (TXA) in reducing blood loss during percutaneous nephrolithotomy (PCNL). MATERIALS AND
methodsA total of 99 patients with renal calculi were recruited for this study over a period of 18 months. Subjects were selected from patients presenting with a history of flank pain in the Outpatient Department (OPD). Written informed consent for the inclusion of patient data in the study was obtained from all participants. The study was undertaken after obtaining ethical clearance from the Institutional Ethics Committee.
resultsIn this study, there was no statistical difference in gender between the groups receiving TXA and those not receiving it (p-value = 0.492). The mean age of the recruited cases in both groups was between 42 and 43 years. This study recorded calyceal puncture sites, irrigating fluid used, and pre- and postoperative hemoglobin and packed cell volume (PCV) values to calculate blood loss. Additionally, body mass index (BMI), co-morbidities, stone size, ease of puncture and dilatation, and operative time were recorded as other variables for both groups. There was no mortality observed in any of the patients postoperatively. Blood loss was much lower in patients receiving TXA.
conclusionTXA is safe and effective in reducing blood loss during PCNL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.